| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 8017.0 | 7587.0 | 6573.7 |
| Other income | 106.1 | 134.2 | 154.9 |
| Total income | 8123.1 | 7721.2 | 6728.6 |
| Profit before exceptional items & tax | 1324.8 | 2057.2 | 1920.6 |
| Exceptional items | 18.2 | 397.5 | 0.0 |
| Profit before tax | 1306.6 | 1659.7 | 1920.6 |
| Net profit | 939.8 | 1272.5 | 1466.8 |
| Operating margin | 16.1% | 21.5% | 28.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -35.90% |
|---|---|
| Net profit, quarter on quarter | -26.10% |
| Revenue, year on year | +22.00% |
| Operating profit, year on year | -31.00% |
| Operating profit, quarter on quarter | -36.60% |
BSE results filing, NSE: ZYDUSLIFE. Figures extracted from the filing.
Zydus Lifesciences Ltd: key numbers
- Share price
- ₹1,159.50
- Market cap
- ₹1,16,673 Cr
- Revenue (annual)
- ₹27,148 Cr
- Net profit (annual)
- ₹5,040 Cr
- P/E (TTM)
- 25.9×Sector 47.4×
- Promoter holding
- 75.01%+0.01% QoQ
- FII holding
- 6.89%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zydus Lifesciences Ltd
All →Zydus Lifesciences Business Update
Zydus Lifesciences announced that a recent USFDA inspection of its pharmacovigilance and post-marketing surveillance system at the company’s USA office concluded with nil observations.
Zydus Lifesciences Credit Rating
CRISIL reaffirmed Zydus Lifesciences ratings: CRISIL AAA/Stable (LT) and A1+ (ST) on a Rs.4,724 Cr bank facility, plus CPs and NCDs. The stable outlook signals unchanged strong credit standing.
Zydus Lifesciences Legal & Regulatory
Zydus Lifesciences' subsidiary, ZPUI, settled an antitrust litigation case for a total payment of USD 5.9 million, without admission of wrongdoing.
- Value
- ₹55.46 Cr
Zydus Lifesciences Business Update
Zydus Lifesciences announced positive Phase II(b) clinical trial results for Saroglitazar Mg in MASH. The global study successfully met its primary endpoint of resolution of steatohepatitis.
- Execution
- 52 weeks
Zydus Lifesciences Merger & Restructuring Worth ₹5 Cr
Zydus Lifesciences Limited has incorporated a wholly owned subsidiary, Zydus Global Treasury Centre IFSC Limited, in GIFT City, Gujarat. The subsidiary has a paid-up capital of Rs. 5 Crore.
- Value
- ₹5.00 Cr
Zydus Lifesciences Promoter Buying (Off-Market)
Zydus Lifesciences announced the transmission of 32,577 equity shares from Late Jasodaben Babubhai Patel to Mr. Prashant Babubhai Patel, both within the Promoter Group.